Investigating outcomes and treatment of long coronavirus disease 2019 in patients with multiple sclerosis treated with rituximab: A case series study
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, characterized by the destruction of the myelin sheath of nerves. MS patients treated with rituximab, an immunosuppressive drug, experience reduced immunoglobulin levels, which increases their risk of variou...
Saved in:
| Main Authors: | Kiana Shirani, Farzin Khorvash, Alireza Karamshahi, Asieh Maghamimehr |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-05-01
|
| Series: | Journal of Research in Medical Sciences |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jrms.jrms_150_25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Persistent hypogammaglobulinemia after rituximab therapy in pediatric patients, prevalence and clinical outcomes
by: Susanna P.C. Höppener, et al.
Published: (2025-06-01) -
The use of “Acellbia” – a biosimilar of rituximab in systemic sclerosis
by: L. P. Ananyeva, et al.
Published: (2023-08-01) -
Safety and tolerability of rituximab in the treatment of systemic sclerosis
by: L. A. Garzanova, et al.
Published: (2023-04-01) -
Intravenous immunoglobulin for intensive therapy of fibrosing alveolitis in a patient TOC \o "1-5" \h \z with systemic sclerosis
by: R T Alekperov, et al.
Published: (2004-02-01) -
Resolution of hypogammaglobulinemia-associated recurrent Campylobacter bacteraemia after hematopoietic cell transplantation (HCT)
by: Emmanouil Karofylakis, MD, et al.
Published: (2025-02-01)